Today: 22 January 2026
Subscribe
Browse Category

NYSE:LLY News 19 January 2026 - 21 January 2026

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

New York, January 21, 2026, 17:20 EST — After-hours Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug. (Stock Titan) The Breakthrough Therapy program aims to fast-track the development and review of drugs for serious…
21 January 2026
·····
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s shares edged up 0.3% to close Tuesday at $1,041.29, then ticked 0.04% higher in after-hours action. The move followed news that the U.S. FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The change is slight, but it hits home as investors keep…
21 January 2026
·····
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

New York, Jan 20, 2026, 10:57 (EST) — Regular session Eli Lilly and Company shares (LLY) nudged up Tuesday following news of a U.S. FDA Breakthrough Therapy designation for its experimental ovarian-cancer drug. The stock traded around $1,040.38, up roughly 0.2%, after starting the session at $1,020 and dipping to a low of $1,019.66. Meanwhile, the SPDR S&P 500 ETF…
20 January 2026
····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

New York, Jan 19, 2026, 10:08 EST — Market closed Eli Lilly and Company shares drew attention heading into Tuesday’s U.S. session, following a Friday close in the green. Investors digested new developments in the obesity-drug sector, a key driver behind the drugmaker’s recent surge. The key question now: does the early appetite for new, easier-to-swallow weight-loss pills alter the…
19 January 2026
····

Stock Market Today

  • Carter's Share Price Recovery May Exceed Fundamentals After Sharp Recent Declines
    January 21, 2026, 10:40 PM EST. Carter's (CRI) shares closed at US$38.17, rebounding 3.8% in a week and 19.1% over 30 days, despite long-term declines-27.1% over one year and 50.8% over five years. The stock scores 2 out of 6 on valuation checks, with its Discounted Cash Flow (DCF) model estimating an intrinsic value around $18 per share, implying current shares are overvalued by 112%. Carter's P/E ratio stands at 16.0x, below industry and peer averages, suggesting market cautiousness. These mixed signals raise questions about whether Carter's price rebound fully reflects its financial fundamentals, underscoring investor caution amid sector-wide challenges in consumer durables.
Go toTop